Trial Profile

Phase I study of CFAK-C4 + gemcitabine in patients with pancreatic cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 Jan 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CFAK C4 (Primary) ; Gemcitabine
Indications Pancreatic cancer
Focus Adverse reactions

Most Recent Events

19 Jan 2011 CureFAKtor Pharmaceuticals have received Orphan Drug Designation for CFAK-C4 for the treatment of pancreatic cancer, according to a CureFAKtor media release
19 Jan 2011 The study will be initiated in 2012, according to a CureFAKtor Pharmaceuticals media release
19 Jan 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com